NSA2

Across TCGA pan-cancer cohorts, NSA2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NSA2 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NSA2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NSA2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where NSA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.633	0.933	<.001	75	view →
CCRCC	DFS	Median	III,IV	0.334	0.835	.003	37	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.841	.005	22	view →
HNSC	DFS	Tertile	III,IV	0.697	0.913	.007	17	view →
LUAD	DFS	Quartile	All	0.556	1.000	.007	15	view →
UCEC	DFS	Tertile	III,IV	1.000	0.383	.016	8	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NSA2–PDAC (DFS)

Open the PDAC breakdown →